In the 80-year history of hormone therapy, it has been alternately embraced and rejected. Case in point: the original term, hormone replacement therapy, came to be seen as highlighting a negative state, and was changed to simply hormone therapy. Why has the pendulum swung so frequently back and forth? What is the latest "timing hypothesis," and will it again change our evaluation of hormone therapy? Host Dr. Bruce Bloom explores the studies and new thinking, the benefit for bone density, the risk of breast cancer, and more, with Dr. Isaac Schiff, chief of the Vincent Obstetrics and Gynecology Service at Massachusetts General Hospital and the Joe Vincent Meigs Professor of Gynecology at Harvard Medical School.
Facebook Comments